A Trial Comparing the Effectiveness and Tolerability of Medications in Older Adults With Stable Angina and Multiple Chronic Conditions: LIVEBETTER
Yale University
Summary
To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
Description
Single-blind, randomized (1:1) pragmatic trial comparing Beta-Blocker therapy versus Calcium Channel Blocker therapy in older adults with symptomatic SIHD and MCC with plans to initiate medical treatment with anti-anginal therapy. Study Aims Aim 1: To compare the effectiveness of anti-anginal medications to improve the symptoms, function, and quality of life among older adults with multiple chronic conditions presenting with stable angina. Aim 2: To compare the tolerability and safety of commonly used anti-anginal medications in older adults with multiple chronic conditions presenting with st…
Eligibility
- Age range
- 65+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: OLDER ADULTS WITH SIHD AND MCC * Age ≥65 years * ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS) * Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following: 1. positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease 2. coronary angiography with stenosis ≥70% in a coronary artery ≥2 mm in diameter or ≥50% stenosis of left main 3. Invasive coronary angiography with positive physiologic tes…
Interventions
- OtherClinician Discretion
Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.
- DrugBeta blocker
Selection of the specific BB and initial starting dose will be determined by the treating clinician.
- DrugCalcium channel blocker
Selection of the specific CCB and initial starting dose will be determined by the treating clinician.
Locations (10)
- Yale School of MedicineNew Haven, Connecticut
- Wellstar Research InstituteMarietta, Georgia
- Cook County HealthChicago, Illinois
- Brigham and Women's HospitalBoston, Massachusetts
- Mt. Sinai Health SystemNew York, New York
- NYC Health and Hospitals, Harlem HospitalNew York, New York